Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
💎 Access the Market Tools Trusted by Thousands of Investors Get Started
Close

Kiniksa Pharmaceuticals Ltd (KNSA)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Kiniksa Pharma's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
16.64 -0.50    -2.92%
22/09 - Closed. Currency in USD ( Disclaimer )
After Hours
16.65
+0.01
+0.06%
16:51:30 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 207,473
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 16.52 - 17.18
Kiniksa Pharma 16.64 -0.50 -2.92%

KNSA Income Statement

 
Featured here, the Income Statement (earnings report) for Kiniksa Pharmaceuticals Ltd, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Income Statement
Collapse All
Period Ending: 2023
30/06
 2023
31/03
 2022
31/12
 2022
30/09
Total Revenue 71.47 48.34 61.88 99.14
Revenue 71.47 48.34 61.88 99.14
Other Revenue, Total - - - -
Cost of Revenue, Total 21.68 15.32 14.23 11.56
Gross Profit 49.79 33.02 47.65 87.58
Total Operating Expenses 74.63 59.54 55.84 52.72
Selling/General/Admin. Expenses, Total 29.18 29.04 27.22 24.68
Research & Development 23.77 15.17 14.39 16.48
Depreciation / Amortization 0.31 0.307 0.308 0.317
Interest Expense (Income) - Net Operating - - -0.459 -
Unusual Expense (Income) - - - -
Other Operating Expenses, Total -0.31 -0.307 0.151 -0.317
Operating Income -3.15 -11.2 6.05 46.41
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets - - - -
Other, Net -1.92 -1.83 -0.794 -0.322
Net Income Before Taxes -1.24 -9.36 6.84 46.74
Provision for Income Taxes -16.21 2.91 2.38 -177.36
Net Income After Taxes 14.97 -12.27 4.46 224.09
Minority Interest - - - -
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 14.97 -12.27 4.46 224.09
Total Extraordinary Items - - - -
Net Income 14.97 -12.27 4.46 224.09
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items 14.97 -12.27 4.46 224.09
Dilution Adjustment -0.071 0.285 0.596 -0.262
Diluted Net Income 15.04 -12.56 3.87 224.36
Diluted Weighted Average Shares 71.63 69.75 71.37 70.55
Diluted EPS Excluding Extraordinary Items 0.21 -0.18 0.054 3.18
DPS - Common Stock Primary Issue - - - -
Diluted Normalized EPS -0.011 -0.084 0.06 0.414
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

KNSA Comments

Write your thoughts about Kiniksa Pharmaceuticals Ltd
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Stephen Appiah
Stephen Appiah Mar 19, 2021 9:28AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I'm surprised no activity there is little activity on this stock.
Reply
1 0
Report
Arl Nn
ArlN Mar 18, 2021 5:15PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The FDA has approved. - ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis- Commercial launch expected in April 2021- Kiniksa launches Kiniksa One Connect™ patient support program
Reply
0 0
Report
Arl Nn
ArlN Mar 15, 2021 6:26PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Breakthrough Therapy designation granted by the FDA for rilonacept for the treatment of recurrent pericarditis, due date is 21st March 2021 under priority review.That should help some movement
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email